



SOLARA
Active Pharma Sciences

Communication Address :
Solara Active Pharma Sciences Limited
"Batra Centre"
No. 28, Sardar Patel Road, Post Box 2630
Guindy, Chennai - 600 032, India
Tel : +91 44 43446700, 22207500
Fax : +91 44 22350278

November 9, 2018

The BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai – 400 001

The National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 541540

Scrip Code: SOLARA

Dear Sir / Madam,

Sub: Announcement under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015

Please find attached press release issued by the Company titled:

“Solara’s Mangalore facility receives Establishment Inspection Report from USFDA”

Thanking you,

Yours faithfully,

For Solara Active Pharma Sciences Limited

S. Murali Krishna
Company Secretary



Encl:- as above

Solara's Mangalore facility receives Establishment Inspection Report from USFDA

Bengaluru, India – November 09, 2018: Solara Active Pharma Sciences Ltd (Solara) (NSE: SOLARA; BSE Code: 541540), a leading Active Pharmaceutical Ingredient provider today announced the completion of USFDA inspection at its multi-product API facility in Mangalore. As part of GMP compliance audit, the Company has received Establishment Inspection Report (EIR) from USFDA, thereby confirming the closure of the inspection in July 2018.

Solara's Mangalore facility is one amongst the four USFDA approved facilities in the Company. It houses six clean rooms with best in class infrastructure for the development and manufacture of niche APIs and API Intermediates. In addition to the USFDA, the site is also approved by TGA (Australia), KFDA(Korea) and WHO (Geneva) and has four CEPs for its APIs with more in the pipeline. It has filed 30+ drug master files covering USFDA, Europe, WHO, Australia, Canada with several more APIs in the pipeline for future filings.

About Solara

Solara Active Pharma Sciences Ltd (BSE-541540, NSE-SOLARA) headquartered in Bengaluru, India offers a basket of diversified, high-value Commercial APIs and Contract manufacturing services in over 75 countries. It has a manufacturing base comprising five API facilities in India with approvals including the USFDA, EU GMP, KFDA and PMDA in Japan.

Investor / Analyst contact

Dikshita Jain

Christensen Investor Relations

✉ djain@christensenir.com

☎ +91 22 4215 0210

Statutory contact

Murali Krishna S

Raghavan. V

✉ investors@solara.co.in

☎ +91 44 4344 6700

Disclaimer: Certain statements in this document that are not historical facts are forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. Solara Active Pharma Sciences Ltd will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.